RB-164 is a first-in-class Fc-silenced ADC targeting tumors expressing ROR-1.
ROR-1: ROR-1 is highly expressed in embryonic tissue, and a variety of hematological malignancies and solid tumors. ROR-1 expression is low in healthy adult cells but is closely related to disease progression and treatment response in cancer. This makes ROR-1 an attractive therapeutic target for anti-cancer drug development.
‘Best in Class Potential’:
RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1 and site specific conjugation of a novel linker to deliver a homogeneous Drug-to-Antibody ration (DAR) and prevent retro-Michael elimination (high stability), all of which provide improved pharmacokinetic and toxicity profiles.
RB-164 demonstrates superior efficacy against a range of human tumors expressing ROR-1 such as triple negative breast cancer (TNBC), lung cancer (NSCLC), ovarian cancer and lymphoma. RB-164™ has also shown efficacy in an ENHERTU™-resistant human tumor model.
An Investigational New Drug (IND) application for RB-164 (SYS6005) has been cleared by China’s regulatory agency, the National Medical Products Administration (NMPA). RB-164 is currently being investigated by CSPC in a Phase 1 dose escalation clinical trial in advanced liquid and solid tumors in China. An IND application with the USA Food & Drug Administration (FDA) to execute the clinical development of RB-164 has also been approved. Radiance will be responsible for the clinical development of RB-164 in the US and other licensed territories.
MORE DETAILS CAN BE PROVIDED ON REQUEST